Loading…
Mauna Kea Technologies and Tasly Pharmaceuticals formed a joint venture to develop, manufacture and commercialize Cellvizio in China and globally for neurology and neurosurgery. Mauna Kea will receive $10 million in cash, a 44.1% equity stake, and a 5-year purchase commitment.